Skin rashes associated with the administration of the 2-nitroimidazole, misonidazole.
Misonidazole, a 2-nitroimidazole, is receiving extensive trial as a radiosensitizing drug in the treatment of patients with malignant disease. Drug sensitivity rashes have been observed and the collected cases from three centers are reported. Of a total of 380 patients there were five (1.3%) instances of definite rash and ten (2.6%) instances of observed rash. These figures are compared with the incidence of sensitivity rashes with other drugs in the nitroimidazole group.
D000328:Adult; D000368:Aged; D003875:Drug Eruptions / Q000209:etiology*; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects*; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D009593:Nitroimidazoles / Q000009:adverse effects*
D009593:Nitroimidazoles; D008920:Misonidazole